30th January 2012 -- Smith & Nephew, (LSE: SN; NYSE: SNN), the global medical technology business, today announces that its UK subsidiary has acquired the Aderma range of Dermal Pads from Focus Product Development Limited.
“Pressure Ulcer prevention is one of the focus areas for the NHS to increase care and reduce costs,” commented Simon Beard, UK & Ireland General Manager. “Up to one in ten patients admitted to hospitals will acquire a pressure ulcer, costing potentially £2.1bn per year. We are excited to add this leading treatment to our portfolio of advanced wound care products and believe it is another step forward in helping our customers to reduce the human and economic costs of wound care.”
Developing skin damage causes great discomfort to the patient and depending on the grade of the ulcer can take many weeks to heal whilst the majority of pressure ulcers can be prevented. The Aderma Dermal Pads are made from a unique polymer gel that redistributes pressure, allowing clinicians to protect bony prominences to help prevent skin damage.
Craig Barson, Managing Director of Focus Product Development Limited, commented: “With Smith & Nephew acquiring the rights to Aderma, the product will receive the sales support opportunities and recognition it truly deserves.”
Enquiries
Investors/Analysts
Phil Cowdy
+44 (0) 20 7401 7646
Media
Charles Reynolds
+44 (0) 20 7401 7646
Andrew Mitchell / Justine McIlroy
+44 (0) 20 7404 5959
Brunswick
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine, Trauma and Clinical Therapies. The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide. Annual sales in 2010 were nearly $4.0 billion.
Smith & Nephew is dedicated to helping improve people’s lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust.
About Aderma Dermal Pads
Aderma Dermal Pads are a simple and effective pressure ulcer prevention device that reduces and redistributes pressure away from critical areas of the body whilst simultaneously transferring frictional force away from the skin. The pads are not adhesive which encourages regular removal and inspection of the skin which is key to any prevention policy. A recent evaluation of the product in a large hospital showed that using Aderma as part of their prevention policy contributed to an 87% overall reduction in hospital-acquired pressure ulcers, and to a decline of 75% in the overall number of pressure ulcers. The products were described by staff as “easy to use” and “simple and effective in protecting vulnerable areas”.
The Aderma Dermal pads are available in a range of different shapes and sizes, including sheets, strips, heel and sacrum. The pads can be used in conjunction with pressure relieving mattresses, cushions, and skin care barrier creams and films. They are for single patient use only but can be washed and re-used by the same patient.
For more information about Aderma, please visit www.aderma.info.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
